Valuation: AstraZeneca PLC

Market Cap 264B 236B 219B 198B 370B 25,098B 374B 2,614B 1,041B 13,133B 989B 968B 41,694B P/E 2026 *
22.2x
P/E 2027 * 19x
Enterprise Value 284B 255B 236B 214B 399B 27,067B 404B 2,819B 1,123B 14,164B 1,066B 1,044B 44,964B EV / Sales 2026 *
4.49x
EV / Sales 2027 * 4.11x
Free-Float
96.62%
Yield 2026 *
1.97%
Yield 2027 * 2.09%
1 day+2.89%
Current month+87.64%
Current year+89.36%
Current year 89.04
Extreme 89.04
175.35
1 year 80.48
Extreme 80.48
175.35
3 years 60.47
Extreme 60.47
175.35
5 years 52.65
Extreme 52.65
175.35
10 years 25.55
Extreme 25.55
175.35
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Chief Operating Officer 55 01/06/2015
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
+2.92%+0.63% - - 264B
+6.61%+5.65%+69.69%+144.02% 1,148B
+1.49%+2.73%+47.32%+86.97% 652B
+1.56%+1.82%+28.97%+104.64% 505B
+0.97%+2.52%+54.38%+66.60% 384B
+5.03%+0.17%+70.36%+43.65% 348B
+2.71%+2.98%+34.74%+56.82% 294B
+2.38%+0.55%+3.92%+27.74% 264B
+2.40%+3.51%+58.68%+75.91% 244B
+1.68%+3.19%+36.88%+108.56% 197B
Average +2.82%+1.39%+44.99%+79.44% 448.57B
Weighted average by Cap. +3.48%+1.50%+50.47%+94.07%

Financials

2026 *2027 *
Net sales 63.32B 56.81B 52.53B 47.57B 88.88B 6,031B 89.95B 628B 250B 3,156B 238B 233B 10,019B 67.37B 60.44B 55.88B 50.61B 94.55B 6,416B 95.7B 668B 266B 3,358B 253B 247B 10,659B
Net income 11.75B 10.54B 9.74B 8.83B 16.49B 1,119B 16.69B 117B 46.4B 585B 44.08B 43.15B 1,859B 13.63B 12.23B 11.31B 10.24B 19.13B 1,298B 19.37B 135B 53.86B 679B 51.16B 50.08B 2,157B
Net Debt 20.67B 18.55B 17.15B 15.53B 29.01B 1,969B 29.36B 205B 81.65B 1,030B 77.57B 75.93B 3,270B 13.23B 11.87B 10.97B 9.94B 18.57B 1,260B 18.79B 131B 52.27B 659B 49.65B 48.6B 2,093B
Projected Income Statement - Annual - AstraZeneca PLC
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
29/10/26 $173.98 +2.64% 672,680
28/10/26 $169.51 -0.34% 1,698,109
27/10/26 $170.08 -1.15% 2,905,364
26/10/26 $172.06 +0.33% 3,310,152
23/10/26 $171.49 -0.63% 3,691,383
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - AstraZeneca PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
169.90USD
Average target price
210.05USD
Spread / Average Target
+23.63%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AstraZeneca PLC